Automatic reciprocity of orphan and rare-paediatric designations between regulators
A rare cancer drug designated 'orphan' in the US must reapply in Europe, Japan and elsewhere. Recognising each other's decisions would save small companies months.
Orphan designation (FDA, EMA, MHLW, others) grants fee waivers, protocol assistance and exclusivity, and is applied for separately with different prevalence thresholds and evidence formats. FDA and EMA offer a common application form but decide independently. The proposal is reciprocal recognition: a designation from one stringent regulator is accepted by partners on notification, with local prevalence data required only where the condition's epidemiology plausibly differs.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaOne global paediatric cancer development plan instead of separate FDA and EMA plans
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.
- IdeaAgree in advance how to borrow evidence between similar rare cancers
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.
- IdeaAdopt tumour-agnostic cancer drug labels across regions by reliance, not re-review
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.
- IdeaA standing rulebook for one-patient treatments
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.
- IdeaOne global rare cancer network with n-of-1 and Bayesian trial frameworks
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.
- IdeaA standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.
- IdeaDevelop drugs in children first when the target is a children's target
Shares Regulatory divergence between regions, Rare and paediatric cancers without markets.